We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+1.32%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.45B
AUM Growth
-$11.8M
Cap. Flow
-$571K
Cap. Flow %
-0.02%
Top 10 Hldgs %
40.31%
Holding
207
New
13
Increased
45
Reduced
58
Closed
10

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$8.47M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.05M
3
ISRG icon
Intuitive Surgical
ISRG
+$7.91M
4
BSX icon
Boston Scientific
BSX
+$6.1M
5
GILD icon
Gilead Sciences
GILD
+$5.71M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$20.7M
2
ILMN icon
Illumina
ILMN
+$12.7M
3
ELV icon
Elevance Health
ELV
+$10.4M
4
CNC icon
Centene
CNC
+$6.81M
5
AGN
Allergan plc
AGN
+$6.78M

Sector Composition

Rank Sector Weight
1 Healthcare 95.11%
2 Real Estate 2.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVDL
126
DELISTED
Avadel Pharmaceuticals
AVDL
$2.35M 0.1%
814,588
– –
ENDP
127
DELISTED
Endo International plc
ENDP
$2.19M 0.09%
531,570
– –
HR
128
DELISTED
Healthcare Realty Trust Incorporated
HR
$2.13M 0.09%
68,000
– –
TFX icon
129
Teleflex
TFX
$6.05B
$2.11M 0.09%
6,379
– –
HQY icon
130
HealthEquity
HQY
$8.41B
$2.08M 0.08%
+31,810
New +$2.21M
HOLX
131
DELISTED
Hologic
HOLX
$2.05M 0.08%
42,701
+23,155
+118% +$1.07M
WMGI
132
DELISTED
Wright Medical Group Inc
WMGI
$2.04M 0.08%
68,506
-46,270
-40% -$1.41M
CRL icon
133
Charles River Laboratories
CRL
$11.2B
$2.01M 0.08%
14,167
+3,527
+33% +$478K
BOLD
134
DELISTED
Audentes Therapeutics, Inc
BOLD
$1.99M 0.08%
52,574
– –
AERI
135
DELISTED
Aerie Pharmaceuticals
AERI
$1.97M 0.08%
66,688
-1,808
-3% -$69.7K
MYOK
136
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$1.94M 0.08%
38,600
– –
ARDX icon
137
Ardelyx
ARDX
$1.22B
$1.72M 0.07%
639,370
– –
CLLS
138
Cellectis
CLLS
$277M
$1.72M 0.07%
110,147
-62,888
-36% -$1.12M
ARQL
139
DELISTED
Arqule Inc
ARQL
$1.68M 0.07%
152,110
-97,890
-39% -$681K
ARNA
140
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.64M 0.07%
28,002
-24,260
-46% -$1.25M
NTUS
141
DELISTED
Natus Medical Inc
NTUS
$1.57M 0.06%
+61,219
New +$1.56M
QURE icon
142
uniQure
QURE
$3.03B
$1.54M 0.06%
19,751
– –
GHDX
143
DELISTED
Genomic Health, Inc.
GHDX
$1.54M 0.06%
26,531
– –
SYNH
144
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$1.48M 0.06%
29,027
– –
VRNA
145
DELISTED
Verona Pharma
VRNA
$1.47M 0.06%
275,000
– –
PTGX icon
146
Protagonist Therapeutics
PTGX
$8.79B
$1.47M 0.06%
121,341
-56,084
-32% -$620K
WVE icon
147
Wave Life Sciences
WVE
$1.09B
$1.46M 0.06%
55,955
+25,619
+84% +$718K
DOC icon
148
Healthpeak Properties
DOC
$15.1B
$1.46M 0.06%
45,500
– –
TXMD icon
149
TherapeuticsMD
TXMD
$23.5M
$1.41M 0.06%
+10,836
New +$1.94M
MRTX
150
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.4M 0.06%
13,590
– –
4 5
6
7 8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Tekla Capital Management held 207 positions worth $2.45B, down 0.48% from $2.46B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q2 2019 filing shows 13 new, 45 increased, 58 reduced and 10 closed positions. Its largest new stake was Alcon: 55,369 shares worth $3.44M. The largest sale was Biogen, an estimated $20.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2019 buy was Alcon: 55,369 shares worth $3.44M.
  • Tekla Capital Management added most to Regeneron Pharmaceuticals in Q2 2019, an estimated $8.47M increase.
  • Tekla Capital Management's biggest Q2 2019 reduction was Biogen, cutting an estimated $20.7M.
  • Tekla Capital Management fully exited Centene in Q2 2019, selling an estimated $6.81M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.45B portfolio in Q2 2019.
  • Tekla Capital Management opened 13 new positions and closed 10 in Q2 2019.
  • Tekla Capital Management's portfolio value fell 0.48% quarter-over-quarter to $2.45B.

Based on Tekla Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.